[1]Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J]. CA 
Cancer J Clin, 2018, 68(6): 394-424.
 [2]Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024 [J]. CA Cancer J Clin. 2024, 74(1):12-49.
 [3]Torre L A, Bray F, Siegel R L, et al. Global cancer statistics, 2012 [J]. CA Cancer J Clin, 2015, 65(2): 87-108.
 [4]Sung H, Ferlay J, Siegel R L, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries [J]. CA 
Cancer J Clin, 2021, 71(3): 209-49.
 [5]Loibl S, Poortmans P, Morrow M, et al. Breast cancer [J]. Lancet. 2021, 397(10286):1750-1769.
 [6]Xiong X, Zheng LW, Ding Y, et al. Breast cancer: pathogenesis and treatments[J]. Signal Transduct Target Ther. 2025, 10(1):49.
 [7]Chen W, Yang J, Fang H, et al. Relevance Function of Linc-ROR in the Pathogenesis of Cancer [J]. Front Cell Dev Biol. 2020, 8:696.
 [8]Peña-Flores JA, Enríquez-Espinoza D, Muela-Campos D, et al. Functional Relevance of the Long Intergenic Non-Coding RNA Regulator of Reprogramming (Linc-ROR) 
in Cancer Proliferation, Metastasis, and Drug Resistance [J]. Noncoding RNA. 2023, 9(1):12.
 [9]Mi Y, Li Y, He Z, et al. Upregulation of Linc-ROR Promotes the Proliferation, Migration, and Invasion of Gastric Cancer Cells Through miR-212-3p/FGF7 Axis [J]. Cancer 
Manag Res. 2021, 13:899-912.
 [10]Tan YT, Lin JF, Li T, et al. LncRNA-mediated posttranslational modifications and reprogramming of energy metabolism in cancer. Cancer Commun (Lond) [J]. 2021, 
41(2):109-120.
 [11]Bhan A, Soleimani M, Mandal SS. Long Noncoding RNA and Cancer: A New Paradigm [J]. Cancer Res. 2017, 77(15):3965-3981.
 [12]Smolarz B, Zadrożna-Nowak A, Romanowicz H. The Role of lncRNA in the Development of Tumors, including Breast Cancer [J]. Int J Mol Sci. 2021, 22(16):8427.
 [13]Ma Y, Zhang P, Wang F, et al. The relationship between early embryo development and tumourigenesis [J]. J Cell Mol Med, 2010, 14(12): 2697-701.
[14]Loewer S, Cabili M N, Guttman M, et al. Large intergenic non-coding RNA-RoR modulates reprogramming of human induced pluripotent stem cells [J]. Nat Genet, 2010, 
42(12): 1113-7.
 [15]Wang Y, Xu Z, Jiang J, et al. Endogenous miRNA sponge lincRNA-RoR regulates Oct4, Nanog, and Sox2 in human embryonic stem cell self-renewal [J]. Dev Cell, 2013, 
25(1): 69-80.
 [16]Hou P, Zhao Y, Li Z, et al. LincRNA-ROR induces epithelial-to-mesenchymal transition and contributes to breast cancer tumorigenesis and metastasis [J]. Cell Death Dis, 
2014, 5(6): e1287.
 [17]Chen W, Wang H, Liu Y, et al. Linc-RoR promotes proliferation, migration, and invasion via the Hippo/YAP pathway in pancreatic cancer cells [J]. J Cell Biochem, 2020, 
121(1): 632-41.
 [18]Li C, Zhao Z, Zhou Z, et al. Linc-ROR confers gemcitabine resistance to pancreatic cancer cells via inducing autophagy and modulating the miR-124/PTBP1/PKM2 axis [J]. 
Cancer Chemother Pharmacol, 2016, 78(6): 1199-207.
 [19]Chen Y M, Liu Y, Wei H Y, et al. Linc-ROR induces epithelial-mesenchymal transition and contributes to drug resistance and invasion of breast cancer cells [J]. Tumour 
Biol, 2016, 37(8): 10861-70.
 [20]Li X, Sun D, Zhao T, et al. Long non-coding RNA ROR confers arsenic trioxide resistance to HepG2 cells by inhibiting p53 expression [J]. Eur J Pharmacol, 2020, 872: 
172982.
 [21]Mohebi M, Sattari A, Ghafouri-Fard S,et al. Expression profiling revealed up-regulation of three lncRNAs in breast cancer samples [J]. Exp Mol Pathol. 2020, 
117:104544.
 [22]Zhao T, Wu L, Li X, et al. Large intergenic non-coding RNA-ROR as a potential biomarker for the diagnosis and dynamic monitoring of breast cancer [J]. Cancer Bio
mark, 2017, 20(2): 165-73.
 [23]Ma J, Yang Y, Huo D, et al. LincRNA-RoR/miR-145 promote invasion and metastasis in triple-negative breast cancer via targeting MUC1 [J]. Biochem Biophys Res Com
mun, 2018, 500(3): 614-20.
 [24]Luo C, Cao J, Peng R, et al. Functional Variants in Linc-ROR are Associated with mRNA Expression of Linc-ROR and Breast Cancer Susceptibility [J]. Sci Rep, 2018, 
8(1): 4680.
 [25]Wen X, Wu Y, Lou Y, et al. The roles of Linc-ROR in the regulation of cancer stem cells [J]. Transl Oncol. 2023, 28:101602.
 [26]Zhou Q, Guo J, Huang W, et al. Linc-ROR promotes the progression of breast cancer and decreases the sensitivity to rapamycin through miR-194-3p targeting MECP2 [J]. 
Mol Oncol, 2020, 14(9): 2231-50.
 [27]Eades G, Wolfson B, Zhang Y, et al. lincRNA-RoR and miR-145 regulate invasion in triple-negative breast cancer via targeting ARF6 [J]. Mol Cancer Res, 2015, 13(2): 
330-8.
 [28]Chen Y M, Liu Y, Wei H Y, et al. Large intergenic non-coding RNA-ROR reverses gemcitabine-induced autophagy and apoptosis in breast cancer cells [J]. Oncotarget, 
2016, 7(37): 59604-17.
 [29]Peng W X, Huang J G, Yang L, et al. Linc-RoR promotes MAPK/ERK signaling and confers estrogen-independent growth of breast cancer [J]. Mol Cancer, 2017, 16(1): 
161.
 [30]Zhang H Y, Liang F, Zhang J W, et al. Effects of long noncoding RNA-ROR on tamoxifen resistance of breast cancer cells by regulating microRNA-205 [J]. Cancer 
Chemother Pharmacol, 2017, 79(2): 327-37.
 [31]Zhao T, Wu L, Li X, et al. Large intergenic non-coding RNA-ROR as a potential biomarker for the diagnosis and dynamic monitoring of breast cancer [J]. Cancer Bio
mark, 2017, 20(2): 165-73.
 [32]Hou L, Tu J, Cheng F, et al. Long noncoding RNA ROR promotes breast cancer by regulating the TGF-β pathway [J]. Cancer Cell Int, 2018, 18: 142.
 [33]He Y, Liu H, Chen Q, et al. Relationships between SNPs and prognosis of breast cancer and pathogenic mechanism [J]. Mol Genet Genomic Med, 2019, 7(9): e871.
 [34]Hou L, Tu J, Cheng F, et al. Long noncoding RNA ROR promotes breast cancer by regulating the TGF-β pathway [J]. Cancer Cell Int. 2018, 18:142.